adenosine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 9 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ansley, K; D'Agostino, RB; Douglas, E; Hundley, WG; Jordan, JH; Kotak, A; Melin, S; O'Connell, NS; Park, S; Romitti, PA; Sorscher, S; Thomas, A; Vasu, S | 1 |
| Bae, S; Cheun, JH; Choi, A; Choi, H; Choi, Y; Chung, J; Han, W; Jung, Y; Kim, BG; Kim, C; Kim, HS; Kim, I; Kim, J; Kim, JY; Kim, N; Kim, O; Kwon, S; Lee, AC; Lee, H; Lee, HB; Lee, S; Lee, W; Lee, Y; Noh, J; Ryu, HS; Ryu, SY; Ryu, T; Shin, K; Song, SW; Yeom, H; Yoo, DK | 1 |
| Bhargavi, N; Chaudhari, D; Date, T; Ghadi, R; Jain, S; Katari, O; Kuche, K | 1 |
| Berchem, G; Chammout, A; Duhem, C; Hasmim, M; Hollier, B; Janji, B; Kumar, A; Mittelbronn, M; Noman, MZ; Oniga, A; Thiery, JP; Van Moer, K; Volpert, M; Xiao, M | 1 |
| Berchem, G; Hasmim, M; Janji, B | 1 |
| Bierau, J; Chen, X; Fan, C; Holler, JM; Kim, B; Li, M; Liu, J; Liu, X; Locasale, JW; Perou, CM; Ptacek, TS; Robinson, A; Rodriguez, J; Simon, JM; Takada, M; von Kriegsheim, A; Xie, L; Zhang, J; Zhang, Q; Zikánová, M; Zurlo, G | 1 |
| Byun, WS; Jarhad, DB; Jeong, LS; Kim, WK; Lee, SK; Yoon, JS | 1 |
| Blackwell, T; Feoktistov, I; Moses, HL; Novitskaya, T; Novitskiy, SV; Owens, P; Vasiukov, G; Ye, F; Zhao, Z; Zijlstra, A | 1 |
| Cai, Y; Li, M; Wu, J; Zhao, G | 1 |
| Chaim, IA; Einstein, JM; Li, H; Madrigal, AA; Meena, JK; Neill, NJ; Nussbacher, JK; Perelis, M; Shankar, A; Tankka, AT; Tyagi, S; Westbrook, TF; Yee, BA; Yeo, GW | 1 |
| Dokic, D; Guo, A; Hamden, R; Hong, A; Jeruss, JS; Lind, H; Oppat, K; Rosenthal, E; Thomas, A; Thomas, AL | 1 |
| Chen, B; Jones, P; Kraus, D; Myers, KA; Palasuberniam, P; Yang, X | 1 |
12 other study(ies) available for adenosine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Myocardial Function in Premenopausal Women Treated With Ovarian Function Suppression and an Aromatase Inhibitor.
Topics: Adenosine; Adult; Age Factors; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Cardiotoxicity; Female; Humans; Magnetic Resonance Imaging; Microcirculation; Middle Aged; Ovary; Pilot Projects; Premenopause; Receptors, Estrogen; Stroke Volume; Triple Negative Breast Neoplasms; Ventricular Function, Left | 2021 |
Spatial epitranscriptomics reveals A-to-I editome specific to cancer stem cell microniches.
Topics: Adenosine; Adenosine Deaminase; Humans; Inosine; Neoplastic Stem Cells; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2022 |
Unfolding the Potency of Adenosine in Targeting Triple Negative Breast Cancer via Paclitaxel-Incorporated pH-Responsive Stealth Liposomes.
Topics: Adenosine; Humans; Hydrogen-Ion Concentration; Liposomes; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
SNAI1-dependent upregulation of CD73 increases extracellular adenosine release to mediate immune suppression in TNBC.
Topics: 5'-Nucleotidase; Adenosine; B7-H1 Antigen; Doxycycline; Humans; Immunosuppression Therapy; Programmed Cell Death 1 Receptor; RNA, Messenger; Snail Family Transcription Factors; Transcription Factors; Triple Negative Breast Neoplasms; Up-Regulation | 2022 |
A role for EMT in CD73 regulation in breast cancer.
Topics: Adenosine; Epithelial-Mesenchymal Transition; Humans; Triple Negative Breast Neoplasms | 2022 |
Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer.
Topics: Adenosine; Adenylosuccinate Lyase; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Female; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; MicroRNAs; Proto-Oncogene Proteins c-myc; Triple Negative Breast Neoplasms | 2019 |
Antiproliferative and Antimigration Activities of Fluoro-Neplanocin A via Inhibition of Histone H3 Methylation in Triple-Negative Breast Cancer.
Topics: Adenosine; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Halogenation; Histone-Lysine N-Methyltransferase; Histones; Humans; Methylation; Triple Negative Breast Neoplasms | 2020 |
Myeloid Cell-Derived TGFβ Signaling Regulates ECM Deposition in Mammary Carcinoma via Adenosine-Dependent Mechanisms.
Topics: 5'-Nucleotidase; Adenosine; Adult; Aged; Animals; Breast; Cancer-Associated Fibroblasts; Carcinogenesis; Datasets as Topic; Extracellular Matrix; Female; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Middle Aged; Myeloid Cells; Receptor, Adenosine A2B; Signal Transduction; Transforming Growth Factor beta; Triple Negative Breast Neoplasms | 2020 |
A ten N6-methyladenosine-related long non-coding RNAs signature predicts prognosis of triple-negative breast cancer.
Topics: Adenosine; Adult; Aged; Biomarkers, Tumor; Female; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Kaplan-Meier Estimate; Middle Aged; Models, Genetic; Prognosis; RNA, Long Noncoding; ROC Curve; Triple Negative Breast Neoplasms | 2021 |
Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer.
Topics: Adenosine; Animals; Breast Neoplasms; Cell Death; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Genes, myc; Humans; Mice, Nude; Mice, Transgenic; Protein Biosynthesis; RNA-Binding Proteins; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells.
Topics: Adenosine; Cell Line, Tumor; Cell Movement; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Female; Humans; NIMA-Interacting Peptidylprolyl Isomerase; Phosphorylation; Protein Binding; Signal Transduction; Smad3 Protein; Transforming Growth Factor beta; Triple Negative Breast Neoplasms | 2017 |
ABCG2 transporter inhibitor restores the sensitivity of triple negative breast cancer cells to aminolevulinic acid-mediated photodynamic therapy.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Survival; Diketopiperazines; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Synergism; Heterocyclic Compounds, 4 or More Rings; Humans; Light; Malonates; Neoplasm Proteins; Photochemotherapy; Photosensitizing Agents; Radiation Tolerance; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |